share_log

Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024

Moomoo 24/7 ·  Apr 18 07:14

Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment